Literature DB >> 19539454

Pulmonary apelin levels and effects in rats with hypoxic pulmonary hypertension.

C U Andersen1, L H Markvardsen, O Hilberg, U Simonsen.   

Abstract

BACKGROUND: The peptide apelin is localised in the vascular endothelium and highly expressed in pulmonary tissue. The aim of this study was to investigate whether apelin could be a potential lung-derived plasma marker for pulmonary hypertension, and study the effect of apelin in pulmonary arteries.
METHODS: Apelin protein levels were measured in the lung, right ventricle, and plasma from normoxic and chronic hypoxic rats with pulmonary hypertension. Isolated intrapulmonary arteries were mounted in microvascular myographs and the effect of apelin investigated. Finally, the distribution of apelin receptors in pulmonary tissue was visualised by immunohistochemistry.
RESULTS: Total pulmonary apelin content was not changed by hypoxia. Right ventricular apelin concentrations and content were lower than in the lung, but increased substantially in hypoxia in correlation with right ventricular pressure. Plasma apelin did not reflect pulmonary or right ventricular apelin levels. In pulmonary arteries from normoxic rats, apelin inhibited vasoconstriction to endothelin-1 and angiotensin-II. However, in arteries from hypoxic rats, apelin failed to inhibit contraction to angiotensin-II and endothelin-1. No difference in immunoreaction for apelin receptors was found in lung sections and arteries from normoxic versus chronic hypoxic rats.
CONCLUSIONS: Apelin changes in the right ventricle seem more specific for pulmonary hypertension than do changes in pulmonary tissue, which does not speak in favour of apelin as a lung-derived marker for this disease. During normoxic conditions, apelin has a modulating effect on vasoconstriction which is lost in chronic hypoxia. This may reflect alterations in the signal transduction downstream of the apelin receptor.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19539454     DOI: 10.1016/j.rmed.2009.05.011

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  18 in total

1.  Apelin attenuates hyperoxic lung and heart injury in neonatal rats.

Authors:  Yvonne P de Visser; Frans J Walther; El Houari Laghmani; Arnoud van der Laarse; Gerry T M Wagenaar
Journal:  Am J Respir Crit Care Med       Date:  2010-07-09       Impact factor: 21.405

Review 2.  Targeting the Wnt signaling pathways in pulmonary arterial hypertension.

Authors:  Vinicio de Jesus Perez; Ke Yuan; Tero-Pekka Alastalo; Edda Spiekerkoetter; Marlene Rabinovitch
Journal:  Drug Discov Today       Date:  2014-06-20       Impact factor: 7.851

3.  Disruption of the apelin-APJ system worsens hypoxia-induced pulmonary hypertension.

Authors:  Suparna M Chandra; Hedi Razavi; Jongmin Kim; Rani Agrawal; Ramendra K Kundu; Vinicio de Jesus Perez; Roham T Zamanian; Thomas Quertermous; Hyung J Chun
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-01-13       Impact factor: 8.311

Review 4.  Vascular effects of apelin: Mechanisms and therapeutic potential.

Authors:  Amreen Mughal; Stephen T O'Rourke
Journal:  Pharmacol Ther       Date:  2018-05-25       Impact factor: 12.310

Review 5.  Apelinergic System Structure and Function.

Authors:  Kyungsoo Shin; Calem Kenward; Jan K Rainey
Journal:  Compr Physiol       Date:  2017-12-12       Impact factor: 9.090

6.  Apelin stimulates glucose uptake through the PI3K/Akt pathway and improves insulin resistance in 3T3-L1 adipocytes.

Authors:  Shunming Zhu; Fei Sun; Weijie Li; Yanjie Cao; Chen Wang; Yabin Wang; Dong Liang; Rongqing Zhang; Shenwei Zhang; Haichang Wang; Feng Cao
Journal:  Mol Cell Biochem       Date:  2011-04-02       Impact factor: 3.396

7.  The Endothelial Prolyl-4-Hydroxylase Domain 2/Hypoxia-Inducible Factor 2 Axis Regulates Pulmonary Artery Pressure in Mice.

Authors:  Pinelopi P Kapitsinou; Ganeshkumar Rajendran; Lindsay Astleford; Mark Michael; Michael P Schonfeld; Timothy Fields; Sheila Shay; Jaketa L French; James West; Volker H Haase
Journal:  Mol Cell Biol       Date:  2016-05-02       Impact factor: 4.272

8.  Apelin and pulmonary hypertension.

Authors:  Charlotte U Andersen; Ole Hilberg; Søren Mellemkjær; Jens E Nielsen-Kudsk; U Simonsen
Journal:  Pulm Circ       Date:  2011 Jul-Sep       Impact factor: 3.017

Review 9.  International Union of Basic and Clinical Pharmacology. CVII. Structure and Pharmacology of the Apelin Receptor with a Recommendation that Elabela/Toddler Is a Second Endogenous Peptide Ligand.

Authors:  Cai Read; Duuamene Nyimanu; Thomas L Williams; David J Huggins; Petra Sulentic; Robyn G C Macrae; Peiran Yang; Robert C Glen; Janet J Maguire; Anthony P Davenport
Journal:  Pharmacol Rev       Date:  2019-10       Impact factor: 25.468

10.  Anticipated classes of new medications and molecular targets for pulmonary arterial hypertension.

Authors:  Nicholas W Morrell; Stephen L Archer; Albert Defelice; Steven Evans; Monica Fiszman; Thomas Martin; Muriel Saulnier; Marlene Rabinovitch; Ralph Schermuly; Duncan Stewart; Hubert Truebel; Gennyne Walker; Kurt R Stenmark
Journal:  Pulm Circ       Date:  2013-01       Impact factor: 3.017

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.